Featured Research Search Results

Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303)

Clinicaltrials.gov identifier:
NCT07491445

Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

Clinicaltrials.gov identifier:
NCT06888921

Treatment
Study for relapsed platinum-sensitive ovarian cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

Clinicaltrials.gov identifier:
NCT07062965

Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Research Study on the Genetics of Breast Cancer

Clinicaltrials.gov identifier:
NCT06773897

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

Clinicaltrials.gov identifier:
NCT06995898

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

The FYI on MRI: A Decision Support Intervention for Screening Breast MRI for Black and Latina Women

Clinicaltrials.gov identifier:
NCT06892275

Surveys, Registries, Interviews
Feedback survey on materials about breast MRI

Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)

Clinicaltrials.gov identifier:
NCT05946213

Treatment
Phase 3 treatment study for high-risk prostate cancer

Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)

Clinicaltrials.gov identifier:
NCT07252232

Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy

Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT06888388

Prevention
Study for people considering double mastectomy to reduce breast cancer risk

Using a Mobile Health App to Improve Quality of Life in Black Men with Prostate Cancer

Clinicaltrials.gov identifier:
NCT06651359

Quality of Life
Quality of life study for Black men with prostate cancer

Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

Clinicaltrials.gov identifier:
NCT07252232

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery

ENGAGE: Surveys to Assess Decision-Making on Genetic Counseling and Testing for Lynch Syndrome

Clinicaltrials.gov identifier:
NCT07106359

Surveys, Registries, Interviews
Clinical trial for untested individuals at risk for Lynch syndrome

Experiences with Genetic Counseling Among Individuals with a BRCA1 or BRCA2 Genetic Mutation

Surveys, Registries, Interviews
Survey for people with a positive BRCA1 and/or BRCA2 mutation.

Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery

Clinicaltrials.gov identifier:
NCT06782932

Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment

Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)

Clinicaltrials.gov identifier:
NCT05554328

Treatment
Phase 2 treatment study for recurrent endometrial cancer

Health and Medicine Decision-Making Study

Surveys, Registries, Interviews
Study for people diagnosed with a complex health condition such as cancer, diabetes or an autoimmune disorder

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations